Objectives This study compared the burden of fatigue between treatment-naïve patients with newly diagnosed acute myeloid leukaemia (AML) and the general population and investigated patient factors associated with fatigue severity.
Methods Pretreatment patient-reported fatigue was assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire in a sample of 463 newly diagnosed patients with AML who were enrolled in a clinical trial. Multivariable linear regression models were used to estimate the adjusted mean differences in fatigue between patients with AML and adults from the general population (n=847) by AML disease risk categories. A clinically meaningful difference in fatigue was defined as ≥3 points. Univariable and multivariable linear regression models were used to identify sociodemographic, clinical and molecular correlates of worse fatigue in patients with AML.
Results Patients with AML reported adjusted mean fatigue scores that were 7.5 points worse than the general population (95% CI −8.6 to −6.4, p<0.001). Across AML disease risk categories, adjusted mean differences in fatigue compared with the general population ranged from 6.7 points worse (patients with favourable risk: 95% CI −8.6 to −4.8, p<0.001) to 8.9 points worse (patients with poor risk, 95% CI −10.5 to −7.2, p<0.001). Overall, 91% of patients with AML reported fatigue that was equal to or worse than the general population’s median fatigue score. Higher pretreatment fatigue was independently associated with female sex, WHO performance status ≥1 and lower platelet levels.
Conclusions Patients with newly diagnosed AML reported worse fatigue than the general population, and mean differences exceeded twice the threshold for clinical significance. Our findings may help to identify patients with AML most likely to benefit from supportive care interventions to reduce fatigue.
- quality of life
- supportive care
- symptoms and symptom management
Data availability statement
Data are available upon reasonable request.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors Conception and design: LBO, FE, FC, DC, AV. Statistical analysis: FC, FE. Data analysis and interpretation: all authors. Manuscript writing: LBO, AV, DC, FC, FE. Final approval of manuscript: all authors.
Funding This work was in part supported by the Associazione Italiana contro le Leucemie, Linfomi e Mieloma (AIL). The grant number is not available as 'AIL' is a non-profit charity organisation which partly funded the original clinical trial. LBO was supported by a National Institutes of Health, National Cancer Institute training grant at the time this work was completed (T32CA193193).
Competing interests ACa: advisory board participation and consultancy: Celgene, Janssen, Merck, Novartis, Gilead, Pfizer, Jazz and Amgen. ATa: grants: Celgene, Roche, Novartis and AbbVie, outside the submitted work. DC: president of FACIT.org. FE: personal fees from AbbVie, Janssen, Orsenix and Takeda, and grants and personal fees from Amgen, outside the submitted work. ML: advisory boards: Celgene, AbbVie, Gilead Sciences, Novartis, Daiichi Sankyo, MSD and Sanofi, outside the submitted work. MPM: advisory board and speaker bureau: Novartis, Astellas, Jazz Pharmaceuticals, Amgen, AbbVie and Janssen; advisory board: Celgene and Pfizer, outside the submitted work. MV: personal fees from Amgen, Millennium Pharmaceuticals, Celgene, Janssen, Novartis and Incyte. All other authors have no conflicts of interest to disclose.
Provenance and peer review Not commissioned; externally peer reviewed.